Takeda Pharmaceutical (TAK) Other Non-Current Assets (2017 - 2026)

Takeda Pharmaceutical's Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $491.1 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 6.6% year-over-year to $491.1 million; the TTM figure through Mar 2026 stood at $491.1 million (up 6.6% YoY), while the FY2026 annual figure was $511.6 million, up 10.88% from the prior year.
• Other Non-Current Assets was $491.1 million for Q1 2026 at Takeda Pharmaceutical, down from $505.5 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $710.9 million in Q1 2022 to a low of $345.6 million in Q1 2024.
• Historically, Other Non-Current Assets has averaged $506.9 million across 5 years, with a median of $478.7 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets tumbled 32.97% in 2023, then jumped 55.3% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $472.6 million in 2022, then declined by 21.7% to $370.1 million in 2023, then jumped by 31.81% to $487.8 million in 2024, then increased by 3.63% to $505.5 million in 2025, then retreated by 2.86% to $491.1 million in 2026.
• The last three Other Non-Current Assets figures came in at $491.1 million (Q1 2026), $505.5 million (Q4 2025), and $478.7 million (Q3 2025), per Business Quant data.